Key Takeaways, With Data for Maryland FDA approvals vary by drug: There are currently three GLP-1s on the market that the FDA ...

Study authors point to semaglutide medication and “behavior changes” as possible reasons for the drop in obesity rates in the ...

Results of the study indicate that Black women in the U.S., ages 66-75, saw the largest decrease in obesity between 2022-2023 ...

Biden officials recently proposed allowing Medicare to start covering GLP-1 medications to treat obesity. It's unclear ...

Some people are not taking weight-loss medications responsibly, the physician says, and don't realize their full implications ...

Doctors might be slow to admit it, but Ozempic and other GLP-1 drugs are making dieting and exercise obsolete.

A doctor, bariatric surgeon and professor say that treatments other than weight-loss drugs are needed to fix the obesity ...

Obesity is down in the US for the first time in a decade. A new study suggests weight-loss drugs may explain why.

The secret agent in the decrease might be semaglutide, a GLP-1 receptor agonist that fuels popular weight loss drugs like ...

He cited a study that found that although the U.S. has the costliest healthcare system in the world, it ranks 42nd in life ...

Popular GLP-1 medications like semaglutide in Ozempic and Wegovy help people lose weight, but what should patients know about ...

Obesity dipped slightly in U.S. adults last year, research found — the first time in more than a decade that the country has ...